Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 1108

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 8
Chunk 1108
---
 
     724  
     6,194 
  
    Other tax receivable 
     309  
     (175)
  
    Prepaid expenses and other current assets 
     1,179  
     2,517 
  
    Prepaid expenses – related party 
     142  
     (108)
  
    Other assets 
     52  
     (32)
  
    Accounts payable and accrued liabilities 
     (1,362) 
     2,695 
  
    Accounts payable and accrued liabilities – related parties 
     (10) 
     26 
  
    Deferred liabilities 
     28  
     (127)
  
    Accrued liability – long-term 
     -  
     (550)
  
    Operating lease liability 
     (25) 
     (4)
  
    Net cash used in operating activities 
     (33,361) 
     (11,980)

    CASH FLOWS FROM FINANCING ACTIVITIES: 

    Net proceeds from sale of common stock and warrants 
     27,789  
     775 
  
    Repayment of debt 
     (10,000) 
     (5,000)
  
    Net proceeds from the exercise of stock options 
     422  
     - 
  
    Net cash provided by (used in) financing activities 
     18,211  
     (4,225)

    Impact on cash from foreign currency translation 
     224  
     (100)

    NET DECREASE IN CASH 
     (14,926) 
     (16,305)
  
    CASH AT BEGINNING OF YEAR 
     35,848  
     52,153 
  
    CASH AT END OF YEAR 
    $20,922  
    $35,848 

    SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION: 

    Cash paid for income taxes 
    $-  
    $- 
  
    Cash paid for interest expense 
    $1,690  
    $1,778 

See accompanying notes to these consolidated financial
statements.

F-6

INMUNE BIO INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – ORGANIZATION AND BASIS
OF PRESENTATION

Organization and Business Overview

INmune Bio